予備分娩に対する陰道プロゲステロン予防 (OPTIMUM研究):多センター,ランダム化,ダブルブラインド試験
Jane Elizabeth Norman1, Neil Marlow2, Claudia-Martina Messow3
1Tommy's Centre for Maternal and Fetal Health, MRC Centre for Maternal and Fetal Health, University of Edinburgh, Edinburgh, UK.
Lancet (London, England)
|February 28, 2016
まとめ
陰道用プロゲステロンは早産や新生児への不良結果のリスクを低下させなかった. この治療は2歳児の発達に長期的な利益も害ももたらさなかった.
科学分野:
- 産婦人科
- 新生児医学
- 発達に関する小児科
背景:
- プロゲステロンの投与は,高リスク妊娠における早産のリスクを減らすことが知られている.
- しかし,プロゲステロンが子供の発達に及ぼす長期的な影響は不明である.
研究 の 目的:
- 新生児と子供の期に Vaginal Progesterone 予防が影響するかどうかを判断する.
- 胎児死亡,新生児合併症,認知発達への影響を調査する.
主な方法:
- 早期出産のリスクのある1228人の女性を対象とした ダブルブラインド ランダム化プラセボ対照試験
- 妊娠22~24週から34週までの間,陰道用プロゲステロン (毎日200mg) を投与した.
- 主なアウトカムには,産科,新生児 (死亡,脳損傷,肺管不形成症の複合体),および子供期 (認知スコア2歳) の測定値が含まれていた.
主要な成果:
- プロゲステロンは,初代産婦人科の結果に有意な効果を示さなかった (OR 0. 86,95%CI 0. 61-1. 22).
- 初次新生児のアウトカム (OR 0. 62, 95% CI 0. 38- 1. 03) に有意な影響は認められなかった.
- 2歳児の認知スコアは,グループによって類似していた (差異 - 0. 48,95%CI - 2. 77から1. 81).
結論:
- 陰道用プロゲステロンは早産のリスクや新生児への不良結果の減少と関連しませんでした.
- この研究では,2歳児の長期的利益や害は認められませんでした.
関連する概念動画
Intrauterine Drug Delivery Systems
124
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
124
Birth Control Methods
7.2K
Vasectomy is a surgical form of male sterilization that involves severing and sealing the vasa deferentia, preventing sperm from mixing with semen during ejaculation. Because a vasectomy does not impact the testes' ability to produce testosterone, hormone levels, libido, and sexual function generally remain unchanged. While vasectomy is highly effective in preventing pregnancy, with a success rate near 99.85%, rare cases of recanalization (spontaneous reconnection) can occur. Although...
7.2K
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
1.5K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.5K
Mitral Valve Prolapse III: Nursing Management
517
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
517
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
595
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
595
Ovarian Cycle
5.1K
The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...
5.1K


